Name | Type | Posted | Actions |
|---|---|---|---|
A0002 HT9402-26-Q-9101 Amend.pdf | Jan 8, 2026 | ||
A0001 February 2026 PandT Meeting Reporting.xlsx | XLSX | Dec 4, 2025 | |
A0001 HT9402-26-Q-9101 Amend.pdf | Dec 4, 2025 | ||
RFQ HT9402-26-Q-9101 CR.pdf | Nov 18, 2025 | ||
https://health.mil/PandT | LINK | Nov 18, 2025 | |
NDC Price List-Antihemophilic Agents - Non-factor Agents.xlsx | XLSX | Nov 18, 2025 | |
NDC Price List FAQ Class Review.pdf | Nov 18, 2025 | ||
NDC Price List-Oncological Agents - Myelofybrosis.xlsx | XLSX | Nov 18, 2025 |
Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/ Uniform Formulary Additional Discount Program
Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/ Uniform Formulary Additional Discount Program
Contact and place of performance
Tracy Banks
San Antonio, TX 78230
USA
The Department of Defense (DoD) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoD Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical e...
View morehe RFQ, including UF BPA and UF ADP appendices are attached here in. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-26-Q-9101. Pre-quotation teleconference is on November 20, 2025. Details are stated in Part 2.4. Pre-Quotation Teleconference.
The Defense Health Agency (DHA), under the TRICARE Management Activity, has issued solicitation HT9402-26-Q-9101 to procure pharmaceutical agents for the Military Health System’s pharmacy benefits program. In accordance with 10 U.S.C. § 1074g, the Department of Defense Pharmacy and Therapeutics (P&T) Committee will evaluate the clinical and cost-effectiveness of specific drugs to determine their placement on the Uniform Formulary. This solicitation specifically focuses on Oncological Agents for Myelofibrosis, including Inrebic, Jakafi, Ojjaara, and Vonjo. The agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the committee's final decisions.
This requirement is classified under NAICS 325412, Pharmaceutical Preparation Manufacturing, and PSC 6505, Drugs and Biologicals. Performance is centered in San Antonio, Texas, and the primary point of contact is Tracy Banks. The solicitation includes eight attachments, such as the Request for Quotation (RFQ), price lists for antihemophilic agents, and amendments reflecting updates through early January 2026. Interested parties are directed to follow the submission instructions and deadlines established in the RFQ document, with a final response deadline of January 16, 2026.
Generated by Lumen AI
Scoped analysis and attachments—go beyond the summary when you need detail from the solicitation package.